Decision Resources, Inc., one of the world's leading research and advisory firms focusing on pharmaceutical and health care issues, finds that Endo Pharmaceuticals and Novartis will become emerging players in the pain management drug market.

"Endo Pharmaceuticals not only has many marketed products for the treatment of pain, but also has one of the deepest pipelines in this area," said Heather Martin, analyst at Decision Resources. "Novartis should move ahead in sales among the pain market players when its cyclooxygenase (COX)-2 inhibitor, Prexige, eventually arrives on the market."

The new DR Pipeline Reports publication entitled Pain Pipeline Analysis: A Treatment Area Poised to Expand, also explains the factors that are making the pain market a lucrative field for pharmaceutical companies. The report finds that the aging population; the increasing number of individuals with diseases and conditions associated with pain, such as cancer, osteoarthritis, and rheumatoid arthritis; and the increasing awareness among medical professionals that pain is undertreated all contribute to the growing market.

About Pain

Approximately 75 million people in the United States suffer from some form of serious pain every year. Despite being a common problem, pain is often undertreated, resulting in unnecessary discomfort or significant suffering. Pain is a significant cause of work absenteeism and a cause of underemployment or unemployment for many individuals.

About DR Pipeline Reports from Decision Resources

DR Pipeline Reports is a series of comprehensive reports that focuses on pharmaceutical and biotech company drug development and commercialization strategies. DR Pipeline Reports expose major players in a therapeutic market and, more importantly, shed light on the emerging players that could significantly impact the current market once their pipelines are launched.

About Decision Resources

Decision Resources, Inc., (http://www.decisionresources.com/) is a world leader in market research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

  For more information, contact:    Elizabeth Marshall    Decision Resources, Inc.    781-296-2563    emarshall@dresources.com 

SOURCE: Decision Resources, Inc.

CONTACT: Elizabeth Marshall of Decision Resources, Inc., +1-781-296-2563,
emarshall@dresources.com

Metabolic Syndrome Drug Market to Increase to Nearly $13 Billion by 2013

View Now